Who is sponsoring NCT06260553?

NCT06260553 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT06260553?

Interventions in NCT06260553: tislelizumab and metronomic oral vinorelbine.

What condition does NCT06260553 study?

NCT06260553 studies EGFR/ ALK-negative Advanced NSCLC.

Is NCT06260553 still recruiting?

NCT06260553 is currently status unknown. Last updated 15 February 2024.

Last reviewed 2024-02-15 · How we verify

NCT06260553

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

Status unknown Phase 2 Last updated 15 February 2024

What this trial tests

Phase 2 trial testing tislelizumab and metronomic oral vinorelbine in EGFR/ ALK-negative Advanced NSCLC in 40 participants. Status unknown.

Timeline

7 February 2024

Primary endpoint
7 February 2025

7 August 2025

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	7 February 2024
Primary completion	7 February 2025
Estimated completion	7 August 2025
Sites	1 location across China

Drugs / interventions tested

tislelizumab and metronomic oral vinorelbine — full drug profile →

Conditions studied

EGFR/ ALK-negative Advanced NSCLC — all drugs for EGFR/ ALK-negative Advanced NSCLC →

Sponsor

Fujian Cancer Hospital

Who can join

Eligibility, any sex, with EGFR/ ALK-negative Advanced NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy of metronomic chemotherapy combination with tislelizumab in EGFR/ALK-negative advanced NSCLC patients intolerant to first-line standard chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.
Wei J, Li W, Zhang P, Guo F, et al · · 2024 · cited 82× · PMID 39725966 · DOI 10.1186/s12943-024-02179-5

Verify or expand the search:

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06260553 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 15 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06260553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing